Pharm-Olam's response to COVID-19 from CEO Rob Davie, PhD. Read Here

Request a Proposal  

Phase I/II Trial Involving Preterm Neonates

An Rare Disease Case Study

Read the Case Study

About the Case Study

Pharm-Olam was contracted to provide clinical research services on a Phase I/II pediatric Respiratory Distress Syndrome study involving neonates with a gestational age between 27 and 33 weeks. This first in-human study required a single intratracheal administration within 24 to 48 hours of birth.

Discover the challenges Pharm-Olam encountered and the solutions implemented in this pediatric study.


Sites & Locations:
12 sites in 3 countries - Great Britain, Germany, and Czech Republic



 

How can we help you create a healthier world?

Talk to one of our experts today.

Please choose one.

Contact Us